From Trends to Translation – Discovery Pharmacology for Alzheimer’s and Parkinson’s Therapies
Alzheimer’s and Parkinson’s disease research continues to gain momentum, with 2025 AD/PD Conference presentations highlighting new targets, disease mechanisms, and therapeutic modalities. Across both academic and industry settings, researchers are prioritizing earlier pharmacological validation and translational alignment to reduce attrition in CNS drug development.
Join Lone Bruhn-Madsen, Chief Scientific Officer, Discovery, and Stefan Ebner Benke, Head of Study Coordination, Scantox Neuro, for "From Trends to Translation – Discovery Pharmacology for Alzheimer’s and Parkinson’s Therapies" on Wednesday, May 21, 2025 | 3:00 PM CEST (9:00 AM EDT). Registrants will receive access to the on-demand recording.
This webinar explores how scientific advances and clinical challenges are shaping the design and application of discovery pharmacology models. We’ll discuss emerging and continued therapeutic focus areas, evolving preclinical model needs, and how in vitro and in vivo systems are being deployed to validate mechanisms, derisk targets, and support progression decisions in Alzheimer’s and Parkinson’s pipelines.
Key Learning Objectives
- Explore in vitro and in vivo discovery pharmacology models used to evaluate mechanism of action, disease relevance, and therapeutic potential.
- Identify model selection strategies based on therapeutic modality, target class, or proposed mechanism.
- Gain practical insights into translational model design and data interpretation for early-stage CNS programs.
Meet The Presenters
Dr. Lone Bruhn Madsen is Chief Scientific Officer for Discovery at Scantox Group, where she leads the scientific direction of a multidisciplinary team spanning neuropharmacology, in vivo models, and discovery services. She is responsible for advancing Scantox’s Discovery platform—guiding the development of robust, decision-enabling models that accelerate the path from target validation to early efficacy. Her leadership ensures scientific rigor and strategic alignment across discovery programs, supporting pharmaceutical innovators in navigating complex early-stage development with confidence.
Dr. Bruhn-Madsen holds a Master’s in Biotechnology Engineering from Aalborg University and a PhD in Medicine from Aarhus University, with research and industry experience in neuroscience, genetics, and preclinical model development.
Dr. Stefan Ebner-Benke brings extensive experience in the design, coordination, and execution of complex nonclinical studies supporting novel neuropharmacological discovery. As Head of Study Coordination at Scantox Neuro, he partners with biotech and pharmaceutical clients to translate early-stage CNS research into actionable data through scientifically rigorous and operationally robust study programs. His multidisciplinary background spans academic research, strategic consulting, and nonclinical operations, with a proven track record of driving excellence in preclinical study delivery. He holds a PhD in Molecular Biology from the University of Vienna, an MSc in Molecular Microbiology from the University of Graz, and an Executive MBA from California Lutheran University.